About us

One of the oldest pharmaceutical companies in the Baltic states
Specializing in generics mostly for the hospital segment
Key products: life–saving medicines, especially in the CNS and cardiovascular therapeutic group
The company complies with the EU GMP requirements.


Egils Kopstals

Egils Kopstals

Chairman of the Board

Ph.D. Juris Hmelnickis

Ph.D. Juris Hmelnickis

Member of the Board

Kaspars Kuprevics

Kaspars Kuprevics

Quality and R&D Director / Member of the Board

Jere Tapani Niemi

Jere Tapani Niemi

Business Development Director


Being responsible for drug and patient safety, JSC «Kalceks» develops adverse drug reaction monitoring (pharmacovigilance) in all countries, where our drugs are available.

«Kalceks» and its mother company «Grindeks» maintains single pharmacovigilance system.

Task of pharmacovigilance division is to eliminate potential risk to patients, and detect of both positive and negative new effects.

Division is guided by Good Pharmacovigilance Practice and national legislation. Received information is verified, evaluated and reported when required.

If using or administering our drugs you notice side effect, lack of efficacy or other unusual reaction, please report it in the way most convenient for you

    by email: [email protected] or [email protected]
    by post: Pharmacovigilance division, JSC Grindeks, Krustpils street 53, LV-1057, Riga, Latvia
    by phone: +371 67083244 (business hours) or +371 22038854 (after business hours)

We guarantee full confidentiality of your data!

We also invite to report about cases of inappropriate drug use!

If you want to report side effects on «Kalceks» drugs, we kindly advise you to use abovementioned options or fill form at homepage of mother company «Grindeks»:

Pharmacovigilance form

Marija Briede
Qualified person for pharmacovigilance

Direct telephone number: +371 22038854

Icon Download pharmacovigilance form (1001.6 KB)